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Introduction
The development of smaller antibody fragments, which 
maintain the antigen affinity of the parental antibody, is 
preferable for better antibody production. Furthermore, 
the advance in smaller fragments production is the 
primary source for the in vitro antibody generation 
systems.
1-3
 The Fv fragment that comprises of variable 
(V) regions is the smallest antigen-binding fragment that 
maintains the parental antibodies antigenicity properties. 
To connect the V regions, a soluble and flexible amino 
acid peptide linker is applied to a scFv (single chain 
fragment variable) fragment.
4-6
 Nowadays, two standard 
formats of recombinant antibodies that are produced in 
eukaryotes expression system are scFv and Fab that 
show relevant for the clinical evaluation purposes.
7
 
Moreover, a fusion of the Fc domain towards antibody 
fragments result in regaining effector functions, stability, 
and avidity.
8,9
 
Recombinant antibodies targeting HIV-1 virus proteins 
have shown a potential in inhibiting the virus replication 
and infectivity. The recombinant antibodies are acting 
either as an intracellular antibody (intrabody) or 
transbody to achieve the requirement effects. Since early 
1990 until 2016, four leading groups and few small 
laboratories had developed eight intrabodies against 
HIV-1 virus proteins. Marasco group focused on the 
generation of intrabodies like anti-Tat, anti-gp120, and 
anti-MA p17.
10-14
 Meanwhile, Pomerantz and colleague 
worked on the production of anti-Rev, integrase, and 
reverse transcriptase intrabodies.
15-17
 Designing of anti-
CCR5, anti-Vif, and integrase intrabodies is the main 
focusing by Barbas III and Goncavales group.
18-20
 In our 
knowledge, there is no works about the establishment of 
anti-CA p24 from anti-p24 hybridoma cell line and used 
as intrabodies in inhibiting the HIV-1 virus replication 
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Abstract 
Purpose: More than half of the diagnostic and therapeutic recombinant protein production 
depends on mammalian-based expression system. However, the generation of recombinant 
antibodies remains a challenge in mammalian cells due to the disulfide bond formation and 
reducing cytoplasm. Therefore, the production of functional recombinant antibodies in 
target cell line is necessary to be evaluated before used in therapeutic application such 
intrabodies against HIV-1. 
Methods: The work was to test expression of a single-chain variable fragment (scFv) 
antibody against HIV-1 Capsid p24 protein in a human mammalian-based expression 
system using HEK293T and Jurkat T cells as a model. Three expression plasmid vectors 
expressing scFv 183-H12-5C were generated and introduced into HEK293T. Expression of 
the scFv was analyzed, while ELISA and immunoblotting analysis verified its binding. The 
evaluation of the recombinant antibody was confirmed by HIV-1 replication and MAGI 
infectivity assay in Jurkat T cells. 
Results: Three plasmid vectors expressing scFv 183-H12-5C was successfully engineered 
in this study. Recombinant antibodies scFv (~29 kDa) and scFv-Fc (~52 kDa) in the 
cytoplasm of HEK293T were effectively obtained by transfected the cells with engineered 
pCDNA3.3-mu-IgGk-scFv 183-H12-5C and pCMX2.5-scFv 183-H12-5C-hIgG1-Fc 
plasmid vectors respectively. scFv and scFv-Fc are specifically bound recombinant p24, and 
HIV-1 derived p24 (gag) evaluated by ELISA and Western blot. Jurkat T cells transfected 
by pCDNA3.3-scFv 183-H12-5C inhibit the replication-competent NL4-3 viral infectivity 
up to 60%. 
Conclusion: Anti-p24 scFv 183-H12-5C antibody generated is suitable to be acted as 
intrabodies and may serve as a valuable tool for the development of antibody-based 
biotherapeutics against HIV-1. 
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and infectivity. Here, we are the first group reporting the 
intrabody. 
Mammalian cells are predominantly used as expression 
hosts for heterologous protein production despite being 
harder to maintain compared to bacteria or yeast. 
Industrial pharmaceutical showed almost up to 50-60% 
of approved recombinant proteins and antibodies were 
produced in mammalian-based cell system.
21
 HEK293T 
is among several cell lines derived from a human 
mammalian cell that used for the production of 
recombinant antibody. Frank Graham established human 
embryonic kidney 293 (HEK293) cells in 1973 at 
experiment number 293 by using DNA of Adenovirus 
5.
22
 DuBridge and the group then developed a cell line 
that stably transfected with the simian virus 40 (SV40) 
large T antigen for use in transient production process.
23
 
The cell line allows the episomal propagation thus 
enhancing the total yield of production process.
24
 The 
cell line also resists against geneticin (G418) as result of 
the expression of neomycin phosphotransferase (Neo) 
selection marker. Therefore, stable transfection with any 
plasmids containing Neo is not possible with this cell 
line.
25
 For last ten years, approximately 15% of scientific 
publications have used HEK cells, and the percentage 
will expectedly increase in the next decade.
26
 
The used of relevant cells in biology assessment is 
important to mimic the real situation of HIV-1/AIDS 
progression. Jurkat T cells are human acute 
lymphoblastic leukemic T cell line that is stably 
producing human interleukin 2.
27,28
 The cell line derived 
from Fred Hutchinson Cancer Research Center and had 
designated as Jurkat-FHCRC. The cells were then 
subjected for limiting dilution to obtain Jurkat Clone E6-
1 that now distributes by ATCC and NIH AIDS Reagent 
Program companies.
29
 The cells have been popularly 
used for biology evaluations with nearly 17,000 Pubmed 
references for Jurkat from late 1980 until 2016. There are 
about 1,320 Pubmed literatures related with Jurkat and 
HIV-1 suggesting the model is a gold standard for 
assessment of HIV-1 replication and infectivity. HIV-1 
Tat increased the CD4 receptor expression of Jurkat cells 
that led susceptibility to HIV-1 virus infection.
30
 In fact, 
HIV-1 infected CD4
+
T can produce up to 10x10
9
 virions 
per day in an infected person and bear a half-life of 2.2 
days.
31
 
In this study, anti-p24 scFv was expressed in the human 
mammalian-based system, and its functional activity was 
evaluated with the hope that antibody-based 
biotherapeutics can be developed as an alternative 
treatment against HIV-1/AIDS. 
  
Materials and Methods 
Bacterial strains and culture conditions 
The E. coli strain DH5α (NEB, #C2987) was used for 
cloning and plasmid propagation purposes. Bacterial 
strains were grown aerobically in Luria-Bertani (LB) 
broth, or on LB agar at 30
o
C, and in the presence of 
Ampicillin (100 µg mL
-1
). Bacterial strains were stored 
in glycerol (50%) -supplemented LB broth at -80°C. 
General molecular biology techniques 
PCR amplifications of DNA fragments intended for 
cloning purposes was carried out using Q5® High-
Fidelity DNA Polymerase (NEB, #M0491), whereas Taq 
DNA Polymerase (NEB, #M0273) was used for routine 
colony PCR. PCR amplified or restricted DNA 
fragments were purified using NucleoSpin® Gel and 
PCR Clean-up kit (Macherey-Nagel GmbH & Co, 
#740609). Plasmid DNA was purified using Wizard® 
Plus SV Minipreps DNA Purification System (Promega, 
#A1465). Vector and insert were mixed in 1:3 molar 
ratios (unless otherwise specified) and ligated in the 
presence of T4 DNA ligase (NEB, #M0202) at 4
o
C for 
18 h. 100 μl of E.coli DH5α as competent cells was 
transformed with 5 μl of vector-insert ligation mix and 
selected on LB agar plates containing 100 μg/mL 
ampicillin at 30°C overnight incubation. For colony 
PCR, at least ten randomly selected bacterial colonies 
were PCR amplified using a vector -specific and an 
insert -specific primer. Plasmid DNA was isolated from 
positive transformants that contained amplicon of 
expected size by PCR and then verified using DNA 
restriction.  
 
Engineering of the scFv expression vectors 
pCDNA3.3-scFv 183-H12-5C 
scFv 183-H12-5C was cloned in pCDNA 3.3_mCherry 
that was obtained from Derrick Rossi (Addgene plasmid 
# 26823). To replace mCherry with scFv insert, inverse 
amplified of pCDNA3.3_mCherry by using pCDNA3.3-
SfiI-R1 and pCDNA3.3-NotI6H-F1 primers (Table 1) 
was performed. The process resulted in the removal of 
mCherry insert and introduction of SfiI (downstream 
CMV promoter) and NotI (upstream TK polyadenylation 
signal) restriction sites. The resulting PCR amplified 
vector backbone was reaction cleaned up and 
sequentially restricted with SfiI and NotI following 
manufacturer’s protocol. A 783 bp of scFv 183-H12-5C 
DNA sequence was amplified from a pHEN2-scFv 183-
H12-5C (46) plasmid using primers scFv 183-H12-5C-
SfiI-F and scFv 183-H12-5C-NotI-R (Table 1) and 
cloned the respective gel purified inserts into the 
pCDNA3.3 at the same sites. The resulting vector was 
named pCDNA3.3-scFv 183-H12-5C (46) and 
transformed into E.coli DH5α. The positive clones were 
screened using vector-specific CMV-F and insert-
specific scFv 183-H12-5C-R primers (Table 1). The 
plasmid was also extracted out before verified using SfiI 
and NotI enzymes  
 
pCDNA3.3-mu-IgGk-scFv 183-H12-5C 
To introduce BsiWI and SfiI restriction sites, the plasmid 
was inverse amplified by using scFv 183-H12-5C-SfiI-F1 
and CMV-BsiWI-R1 primers (Table 2). The process 
resulted in the introduction of BsiWI (downstream CMV 
promoter) and SfiI (upstream scFv 183-H12-5C) 
restriction sites. The resulting PCR amplified vector 
backbone was reaction cleaned up and sequentially 
restricted with BsiWI and SfiI following manufacturer’s 
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protocol. Mouse IgG kappa chain signal peptide (Table 2) 
was oligo annealed in the purified vector. The resulting 
vector was named pCDNA3.3-mu-IgGk-scFv 183-H12-
5C (46) and transformed into E.coli DH5α. The positive 
clones were screened using by using vector-specific 6His-
A-Seq-R and insert-specific BsiWI-MuIgGk-F primers 
(Table 2). The plasmid was also extracted out before 
verified using BsiWI and NotI enzymes. 
 
Table 1. Oligonucleotides used for engineering of pcDNA3.3-scFv 183-H12-5C-6His. Restriction enzyme (italic) and 
its recognition site underline. 
Set Primer name Primer sequence (5’3’) 
For engineering of pcDNA3.3-scFv 183-H12-5C-6His 
1 
pcDNA3.3-NotI6H-F AACGGGCGGCCGCACATCATCATCACCATCACTGAAGGGTTCGATCCCTACCGG  
pcDNA3.3-SfiI-R CCATGGCCGGCTGGGCCGCAGGGTTCGATCCTCTAGAGTCCGG  
2 
scFv 183-H12-5C-SfiI-F CCTGCGGCCCAGCCGGCCATGGCCCAGGTCCAACTGC  
scFv 183-H12-5C-NotI-R GATGTGCGGCCGCCCGTTTCAGTTCCAGTTTGGTC  
For colony PCR of scFv 183-H12-5C in pCDNA3.3 plasmid backbone 
1 
CMV-F CGCAAATGGGCGGTAGGCGTG  
scFv 183-H12-5C-NotI-R GATGTGCGGCCGCCCGTTTCAGTTCCAGTTTGGTC 
 
 
Table 2. Oligonucleotides used for engineering of pcDNA3.3-mu-IgGk-scFv 183-H12-5C-6His. Restriction enzyme 
(italic) and its recognition site underline.  
Set Primer name Primer sequence (5’3’) 
For engineering of pcDNA3.3-mu-IgGkappa-scFv 183-H12-5C-6His 
1 
scFv 183-H12-5C-SfiI-F1 CCTGCGGCCCAGCCGGCCATGGCCCAGGTCCAACTGC  
CMV-BsiWI-R1 CCATCGTACGTCGATCCTCTAGAGTCCGGAG 
2 
Mu IgG k-F 
GTACGATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCA
GGTTCCACTGGTGACGCGGCCCAGC 
Mu IgG k-R 
GGGCCGCGTCACCAGTGGAACCTGGAACCCAGAGCAGCAGTACCCATAGCAG
GAGTGTGTCTGTCTCCATC 
For colony PCR of murine-IgG kappa-scFv 183-H12-5C in pCDNA3.3 plasmid backbone 
1 
BsiWI-MuIgGk-F CGTACGATGGAGACAGACACACTCCTG 
6His-A-Seq-R CCTTCAGTGATGGTGATGATGATGTGC 
 
pCMX2.5-scFv 183-H12-5C-hIgG1-Fc 
scFv 183-H12-5C was cloned in pCMX2.5-hIgG-Fc that 
was obtained from Micheal Hust (Technische Universität 
Braunschweig). To allow the cloning of a scFv insert 
into the vector backbone, the pCMX2.5-hIgG-Fc vector 
was restricted in SYBR® Safe DNA gel using NcoI and 
NotI restriction enzymes following manufacturer’s 
protocol. This resulted in accessible of NcoI 
(downstream CMV promoter) and NotI (upstream hinge-
IgG-Fc sequence) restriction sites. The respective gel 
purified vector was reaction cleaned up. The scFv insert 
was prepared by restricting pHEN2-scFv 183-H12-5C-
6His-myc with NcoI and NotI and cloned the respective 
gel purified inserts into the pCMX2.5-hIgG-Fc at the 
same sites. Both vector and insert were ligated and 
incubated overnight. The resulting vector was named 
pCMX2.5-scFv 183-H12-5C-hIgG-Fc and transformed 
into E.coli DH5α. The positive clones were screened 
using vector-specific CMV-F and insert-specific scFv 
183-H12-5C-NotI-R primers (Table 3). The plasmid was 
also extracted out before verified using NcoI and NotI 
enzymes. 
 
Table 3. Oligonucleotides used for verification of pCMX2.5-scFv 183-H12-5C-hIgG1-Fc. 
Restriction enzyme (italic) and its recognition site underline. 
Set Primer name Primer sequence (5’3’) 
For colony PCR of scFv 183-H12-5C in pCMX2.5 plasmid backbone 
1 
CMV-F CGCAAATGGGCGGTAGGCGTG 
scFv 183-H12-5C-NotI-R GATGTGCGGCCGCCCGTTTCAGTTCCAGTTTGGTC 
 
Cell line and culture conditions 
HEK293T (#CRL-3216) was purchased from American 
Type Culture Collection (ATCC). Jurkat T Clone E6-1 
(#177) was obtained through the NIH AIDS Reagent 
Program, Division of AIDS, NIAID, NIH. Jurkat T cell 
line was maintained in RPMI 1640 supplemented with 
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2mM L-glutamine and 10%FBS at 37°C in a 5% CO2 
incubator. HEK293T cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) at 
37°C in a 5% CO2 incubator. 
 
Transient transfection assay  
X-tremeGENE HP DNA Transfection 
The day before transfection, 293T cells was cultured at 
37°C in 5% CO2 to a density of about 5×10
5
 cells/ml in 
6-well plates in DMEM medium that contained 10% 
heat-inactivated FBS. The cultures were 80% confluent 
on the day of transfection. The scFv vector was 
transfected into 293T cells using the X-tremeGene or 
calcium phosphate. Briefly, X-tremeGENE HP DNA 
Transfection Reagent was used to deliver pCDNA3.3-
mu-IgGk-scFv 183-H12-5C plasmid into HEK293T 
cells. HEK293T cells were seeded at a cell density of 5 x 
10
5
 cells per plate onto a 60-mm tissue culture dishes in 
5 mL DMEM medium containing 10% FBS the day 
before transfection. 5 μg of pCDNA3.3-mu-IgGk-scFv 
183-H12-5C (stock 1mg/mL) plasmid was gently mixed 
with 500 μL of DMEM-serum free medium in 1.5 mL 
tube. Ten μL of X-tremeGENE HP DNA Transfection 
Reagent (2:1) was added directly into diluent without 
any contact with the wall of the tube. The complex was 
gently mixed by pipetting up and down. The transfection 
reagent: DNA complex was incubated for 15 minutes at 
room temperature. The transfection complex was added 
to the cells in a dropwise manner, and the cells were 
incubated for 24 and 48 hours before measuring protein 
expression in the culture supernatant. 
 
Calcium Phosphate Transfection 
Calcium Phosphate transfection was used to deliver 
pCMX2.5-scFv 183-H12-5C-hIgG1-Fc plasmid into 
HEK293T cells. HEK293T cells were seeded at a cell 
density of 5 x 10
5
 cells per plate onto a 60-mm tissue 
culture dishes in 5 mL DMEM medium containing 10% 
FBS the day before transfection. Next day, medium on 
cells was changed three hours before beginning 
transfection. 2 μg of plasmid was gently mixed with 296 
μL of filtered deionized water in 4 mL clear round-bottom 
tube by vortexing on a low setting (1000 rpm for 10 
seconds). 37 μL of 2 M calcium chloride was added to the 
DNA/water mixture and gently mixed by vortexing on a 
low setting. 300 μL of 2X HBS was added into new clear 
round bottom tube and the DNA/water/CaCl2 mixture we 
dropwise added into it and vortexing on a low setting. The 
tube was incubated at room temperature for 30 minutes. 
The mixture was mixed and dropwise added to the pre-
warmed medium on the cells with gently swirling. The 
cells were incubated for 16 hours before changed with 
fresh medium. The culture supernatant was collected after 
48, 72 and 96 hours before continuing with purification.  
 
Neon Transfection System 
For difficult transfected cells such human Jurkat T cell, 
introducing plasmid into this cell was done by 
electroporation using Neon Transfection system. The 
cells were washed with 1X PBS once and diluted to 
3x10
6
 cells/30uL in R-Buffer. 0.3x10
6
 cells (10 μL) were 
gently mixed with pCDNA3.3-scFv 183-H12-5C (3 μg) 
in a sterile 0.2 mL tube. 10 μL of the mixture that 
represents 0.2x10
6
 cells and 2 μg plasmids were used for 
electroporation with parameters; pulse voltage=1300, 
pulse width=10, and pulse number=3. The transfected 
cells were maintained at 0.2x10
6
 cells/mL in pre-warmed 
RPMI 1640 growth medium and incubated at 37°C for 
48 hours to allow cells to recover. The cells were used 
for antiviral assessment. 
 
Purification of scFv 183-H12-5C and scFv-Fc 183-
H12-5C 
The clear supernatant containing soluble scFv 183-H12-
5C-6His was filtered through pre-washed (with 
deionized H2O) 0.45 μm membrane (Millipore, 
#HPWP04700) and diluted 1:1 with equilibrium/wash 
buffer (50 mM sodium phosphate, 300 mM NaCl, 20 
mM imidazole, pH 7.4). The sample was loaded onto a 1 
mL HisPur Cobalt Chromatography Cartridge at a flow 
rate of 1 mL/min. The cartridge was washed with 
equilibrium/wash buffer until the baseline absorbance at 
280 nm was reached. scFv His-tagged was eluted with 
20–150 mM imidazole gradient, collected in 1 mL 
fractions. 
The supernatant containing soluble scFv-Fc 183-H12-5C 
of the transiently transfected cells was applied to 
Pierce™ Chromatography Cartridges Protein G (Pierce 
#89926) on an FPLC system (AKTA purifier 900, GE) 
that had been previously equilibrated with binding buffer 
(50 mM sodium acetate, pH 5.0). The column was 
washed with binding buffer, and protein was eluted with 
a linear imidazole gradient (5-150 mM in 0.1 M glycine, 
pH 2.5). The eluted fractions were collected in tubes that 
contained a neutralizing buffer (1 M Tris-HCl, [pH 8.0]), 
so as to adjust the pH to approximately 7.  
Finally, the purified samples (scFv and scFv-Fc 183-
H12-5C) were dialyzed against PBS. Dialysis was 
performed three times with an exchange of fresh PBS in 
each round. The dialyzed products were lyophilized and 
reconstituted in deionized H2O followed by 
quantification using Qubit Protein fluorometer. The 
purity of the eluted antibody fraction was analyzed by 
SDS-PAGE on 10% gels under reducing conditions. 
Protein bands were visualized by Coomassie blue 
staining. After electrophoresis, the proteins in the gel 
were transferred to a nitrocellulose membrane (GE), 
which was then blocked with 5% skim milk in TBST 
(TBS with 0.05% Tween 20). The membrane was 
incubated with a 1：10,000 dilution of HRP-conjugated 
goat anti-human IgG (KPL) for 1 h at room temperature 
and then washed three times with TBST. After that, the 
immunoreactive bands were visualized using an 
enhanced chemiluminescence detection system (ECL; 
Pierce Thermo). 
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Binding activity of scFv 183-H12-5C and scFv-Fc 183-
H12-5C  
Binding activities of scFv and scFv-Fc antibody were 
determined by western blot and ELISA. For ELISA, 
serially dilutions of scFv 183-H12-5C-6His (160 nM -
10 nM) in coating buffer and 100 µL used to coat 
individual wells of a 96-well microliter plate. Parental 
anti-p24 IgG mAbs (183-H12-5C) were used to coat 
some wells that served as positive control. The plate 
was incubated overnight at 4
o
C and wells were washed 
3X with wash buffer (PBS pH7.4, 0.05% Tween-20). 
Occupied sites were blocked by incubating wells with 
200 µL of blocking buffer (PBS pH7.4, 5% skimmed 
milk) for two h at 25°C followed by 3X washing with 
wash buffer before adding the samples. 100 µL of 
HIV-1 derived p24 (gag) were added to each well, 
lysed with 25 uL of lysis buffer and incubated at 25°C 
for two h. The wells were washed and added with 100 
µL of 33.33 nM (5µg/mL) of HRP-conjugated 
secondary anti-p24 mAb (31-90-25) and incubated at 
25°C in the dark for 1 hour. The wells were washed 
and bound antibody detected by adding 100 µL of 
TMB substrate solution (KPL #52-00-01) for 30 min at 
25
o
C in the dark. The color development was stopped 
by adding 100 µL of 0.5M sulfuric acid and 
absorbance was measured at 450 nm with a reference 
wavelength of 670 nm.  
Meanwhile, for scFv-Fc 183-H12-5C, two dilutions (1 
and 10 ug/mL) of recombinant p24 in coating buffer 
were used to coat individual wells of a 96-well 
microliter plate. The plate was incubated overnight at 
4°C and wells were washed 3X with wash buffer (PBS 
pH7.4, 0.05% Tween-20). Occupied sites were blocked 
by incubating wells with 200 µL of blocking buffer 
(PBS pH7.4, 5% skimmed milk) for two h at 25°C 
followed by 3X washing with wash buffer before 
adding the samples. 100 µL of 1 ug/mL of scFv-Fc 183-
H12-5C were added to each well and incubated at 25
o
C 
for two h. The wells were washed and added with 100 
µL of 33.33 nM (5µg/mL) of HRP-conjugated anti-
human mAb (KPL) and incubated at 25°C in the dark 
for 1 hour. The rest steps as mentioned in above. 
For Western blot, proteins (recombinant P24 or 
inactivated HIV whole virus) were transferred to 
nitrocellulose membrane (GE Healthcare Life 
Sciences, # RPN82D), blocked with blocking buffer 
(5% skimmed-milk proteins in TBS-Tween 20), and 
incubated either with 2 mL of scFv-Fc (1 µg/mL) or 
mAb-IgG 183-H12-5C (1μg/ml) diluted in 5% 
skimmed milk TBS-T for 12 h at 4
o
C. Blots were 
washed 3X with washing buffer (TBS, 0.1% Tween-
20) and bound scFv-Fc and mAb were probed using 
two mL of anti-human IgG-HRP (KPL) and anti-
mouse IgG-HRP respectively, diluted 1:20,000 in 5% 
skimmed milk TBS-T was added and blots incubated at 
25°C for one h. Blots were developed by using 
SuperSignal West Pico reagents after washing 3X with 
washing buffer. 
 
HIV-1 replication analysis 
Jurkat T cells (1x10
5
 cell/well) were transfected with 1 
μg of pCDNA3.3-scFv 183-H12-5C by Neon 
Transfection system. After 48 hours, cells were counted 
and dispensed into 1.5 mL tubes at a cell density of 
1x10
5
 cells/tubes in 0.05 mL complete medium (RPMI 
containing 10% FBS) with 20 μg/mL DEAE-dextran. 
Cells were infected at a multiplicity of infection (MOI) 
of 0.1 with replication-competent HIV-1 NL4.3  
 
MAGI infectivity assay 
MAGI cells were seeded at a cell density of 1 x 10
4
 cells 
per well onto a 96-well plate in 0.1 mL complete DMEM 
the day before infection. Next day, the medium was 
removed and 30 μL viral supernatant diluted in serum-
free DMEM containing 20 μg/mL DEAE-dextran 
(BioBasic, Canada #DB0147) was added to each well. 
The plate was incubated at 37°C, 5% CO2 for two hours 
and 0.2 mL complete media was added. Cells were 
incubated at 37°C, 5% CO2 for two days. Then, cell 
supernatants were removed, and 0.2 mL of fixing 
solution (1% formaldehyde, 0.2% glutaraldehyde in 1X 
PBS) was added to each well. The plate was incubated at 
room temperature for exactly 5 minutes. The fixing 
solution was removed and washed thrice with 0.2 ml 1X 
PBS (pH7.4). Next, cells were stained with 80 μL 
staining solutions per well and incubated at 37°C for 
exactly 50 minutes in the non-CO2 incubator. The 
staining solution was removed and washed thrice with 
1X PBS (pH 7.4). Blue foci were counted 
microscopically using inverted microscope and infection 
levels were recorded as blue focus units (BFU/well). 
Background levels of BFU/well were typically <2 in all 
assays. 
 
Results 
Engineering of pCDNA3.3 -scFv 183-H12-5C 
The inverse PCR of pCDNA3.3 vector resulted in the 
generation of vector plasmid with 5.5 kb (Figure 1B). 
Amplification of insert-specific scFv 183-H12-5C from 
pHEN2-scFv 183-H12-5C (46) plasmid resulted in 
production of insert with 783 bp (Figure 1B). Twelve 
colonies were randomly selected using a combination 
primer set and nine out of twelve were amplified around 
850 bp scFv 183-H12-5C-6His (Figure 1C). Three 
positive colonies were then selected and verified with 
SfiI and NotI restriction enzyme respectively. All clones 
were successfully restricted by detection of linearized 
plasmids as showed in Figure 1D. 
 
Engineering of pCDNA3.3-mu-IgGk-scFv 183-H12-5C 
The inverse PCR of pCDNA3.3-scFv 183-H12-5C vector 
resulted in the generation of vector plasmid with 6.19 kb. 
Oligo annealing of mouse IgG kappa chain signal 
peptide resulted in ligation with the purified vector that 
was verified by amplification of scFv 183-H12-5C-6His 
with 780 bp from twelve randomly transformed colonies 
(Figure 2B). Five positive colonies were then selected 
and further restricted with BsiWI and NotI restriction 
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enzyme respectively. Two clones were successfully 
restricted by detection of ~5.4 kb (pCDNA3.3) and 855 
bp amplicons as showed in Figure 2C.  
 
Engineering of pCMX2.5-scFv 183-H12-5C-hIgG1-Fc 
The restriction of pHEN2-scFv 183-H12-5C (46) 
plasmid vector resulted in generation of scFv 183-H12-
5C (insert) with size ~780 bp. The restriction of 
pCMX2.5-hIgG-Fc plasmid vector resulted in production 
of plasmid vector with 5711 bp size (Figure 3B). 
Twenty-four colonies were randomly selected using a 
combination primer and twenty-one out of twenty-four 
colonies were amplified around 850 bp scFv 183-H12-
5C-6His (Figure 3C). Six positive colonies were then 
selected and verified with NcoI and NotI restriction 
enzymes. All clones were successfully restricted by 
detection of 5.711kb (pCMX2.5-hIgG-Fc) and 780 bp 
(scFv 183-H12-5C) as showed in Figure 3D. 
 
 
Figure 1. Engineering and verification of pCDNA3.3-scFv 183-H12-5C vector. Schematic representation of expression vector 
pCDNA3.3-scFv 183-H12-5C (A). scFv 183-H12-5C gene was amplified from pHEN2-scFv 183-H12-5C, restricted and cloned at SfiI/NotI 
restriction sites in inversely amplification pCDNA3.3 vector (B). Colony PCR used CMV-F/scFv 183-H12-5C NotI-R primers; Presence of 
~860 bp band in most of the clones suggests the presence of scFv 183-H12-5C in pCDNA3.3-scFv 183-H12-5C plasmid vector (C). 
Restriction analysis of pCDNA3.3-scFv 183-H12-5C with SfiI/NotI (Linearized plasmids) (D). 
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Figure 2. Engineering and verification of pCDNA3.3-mu-IgGk-scFv 183-H12-5C vector. Schematic representation of expression 
vector pCDNA3.3-mu-IgGk-scFv 183-H12-5C (A). Colony PCR used BsiWI-muIgGk-F/6His-A-seq-R primers; Presence of ~860 bp band 
in most of the clones suggests the presence of mu-IgGk-scFv 183-H12-5C in pCDNA3.3-mu-IgGk-scFv 183-H12-5C plasmid vector (B). 
Restriction analysis of pCDNA3.3-mu-IgGk-scFv 183-H12-5C with BsiWI/NotI (5.4 kb vector backbone + 855 bp insert) (C). 
 
 
 
Figure 3. Engineering and verification of pCMX2.5-scFv 183-H12-5C-hIgG1-Fc vector. Schematic representation of expression 
vector pCMX2.5-scFv 183-H12-5C-hIgG-Fc (A). scFv 183-H12-5C gene was restricted from pHEN2-scFv 183-H12-5C used NcoI/NotI 
enzymes, gel purified and cloned at NcoI/NotI restriction sites in restricted pCMX2.5-hIgG1-Fc vector (B). Colony PCR used CMV-Seq-
F/scFv 183-H12-5C NotI-R primers; Presence of ~860 bp band in most of the clones suggests the presence of scFv 183-H12-5C in a 
pCMX2.5-scFv 183-H12-5C-hIgG1-Fc plasmid vector (C). Restriction analysis of pCMX2.5-scFv 183-H12-5C-hIgG1-Fc with NcoI/NotI 
(5.4 kb vector backbone + 855 bp insert) (D). 
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Expression of secreted soluble scFv 183-H12-5C and 
scFv-Fc 183-H12-5C 
Since the MBP-scFv 183-H12-5C produced from bacteria 
efficiently bound the recombinant and wild-type HIV-1 
CA p24 (data not shown), it is important to find out if the 
expression of scFvs in reducing cytoplasm of mammalian 
cells would also bind to HIV-1 CA p24. Thus, scFv 183-
H12-5C was cloned into engineered pCDNA3.3 vector 
bearing murine IgGk signal that results in the secretion of 
the soluble scFv in the culture supernatant.  
HEK293T cells were transfected with resulting 
pCDNA3.3-muIgGk-scFv 183-H12-5C vector and culture 
supernatant containing soluble scFv was collected at the 
different time point of post-transfection. In control 
experiments, cells were transfected with parental 
pCDNA3.3_mCherry vector that expressed similar sized 
red fluorescent protein (RFP). Fluorescence microscopic 
analysis showed the transfection efficiency reached 80-
90% which suggested the pCDNA3.3 vector regardless the 
carried gene were suitable to express target protein in 
HEK293T cells (Figure 4A). Western blot using anti-6His 
was performed to confirm the expression of soluble scFv 
183-12H5C. Using standard protocol, the HEK293T cells 
transfected with pCDNA3.3-muIgGk-scFv 183-H12-5C 
vectors produced soluble scFv by detecting the ~29 kDa 
bands. In contrast, no detection of red fluorescence protein 
bands was detected since the protein was not tagged with 
6His (Figure 4B). The optimizing experiment showed 0.2 
μg of pCDNA3.3-muIgGk-scFv 183-H12-5C plasmid is 
the suitable concentration to transfect HEK293T for 
expression of secreted-scFv 183-H12-5C. There was no 
difference between the scFv collected after 24 or 48 hours 
of post-transfection (Figure 4C and 4D).  
 
 
Figure 4. Expression analysis of secreted scFv 183-H12-5C-6His in HEK293T. HEK293T cells were transfected with 0.2 g of 
pCDNA3.3-muIgGk-scFv 183-H12-5C plasmid vector for 48 hours. Expression of control protein was checked by fluorescence 
microscope (A). SDS-PAGE and Western Blot analysis of secreted scFv 183-H12-5C collected at the different time point of post-
transfection (B). Optimization of plasmid concentrations for expression of secreted scFv 183-H12-5C after 24 hours (C) and 48 hours (D) 
of post-transfection. Error bars show standard deviations calculated from at least two independent experiments each done in duplicate. 
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The structure of the scFv-Fc 183-H12-5C antibody 
produced in the reducing environment of HEK293T was 
analyzed by SDS-PAGE and immunoblot. The scFv-Fc 
is expected to be demonstrated as a 52 kDa monomer 
under the reducing conditions as the interaction of CH3 
domains breaks in the presence of a potent surfactant 
such as SDS. As shown in Figure 5B, detection of 52 
kDa bands confirmed that the scFv-Fc 183-H12-5C was 
produced in HEK293T cells. 
 
 
Figure 5. Purification of scFv 183-H12-5C and scFv-Fc 183-H12-5C. Twenty milliliters of supernatant fraction diluted 1:1 with binding 
buffer was applied on HisPur cobalt resin by batch method purification. Following manufacturer’s instruction, scFv 183-H12-5C was eluted 
with elution buffer. SDS-PAGE analysis and of protein fractions from scFv antibodies purification by batch method (A). 100 milliliters of 
supernatant fraction diluted 1:1 with binding buffer was applied on Pierce Chromatography Cartridges Protein G, attached to FPLC system 
(AKTA purifier 900, GE Healthcare). Following manufacturer’s instruction, scFv-Fc 183-H12-5C was eluted with increasing gradient of elution 
buffer. SDS-PAGE analysis and Western blot analysis of protein fractions from scFv-Fc antibodies purification by FPLC (B). 
 
Purification of scFv 183-H12-5C and scFv-Fc 183-
H12-5C 
Since scFvs 183-H12-5C has a hexahistidine tag at its 
amino terminal. Hence, the recombinant antibodies were 
purified using HisPur cobalt resin. As shown in Figure 
5A, a simple spin-column method led to the recovery of 
highly purified scFv 183-H12-5C-6His from the 
supernatant of HEK293T cells. The incubation of the 
soluble fraction at 4°C for overnight resulted in efficient 
binding of scFv 183-H12-5C to the resin bed. Washing 
buffer containing 30 mM of imidazole with six times 
washing steps was able to remove unbound histidine 
protein. The bound histidine protein then eluted for four 
times under acidic condition. Detection of a prominent 
protein band of approximately 28 kDa under reducing 
conditions confirmed that the scFv 183-H12-5C-6His 
was produced in HEK293T cells. 
Since scFv-FC 183-H12-5C has a Fc portion at its amino 
terminal. Hence, the recombinant antibody was purified 
using Protein G based on Streptococcal protein G bind to 
human Fc fragments at β-strand 3 and the α-helix. As 
shown in Figure 5B, purified scFv-Fc 183-H12-5C were 
obtained from the supernatant of HEK293T cells using a 
fast protein liquid chromatography method. Almost all of 
the scFv-Fc 183-12H-5 protein was bound to the Protein 
G when the supernatant was flowed in protein G 
cartridge column with flow rate at 1min/mL. 12 mL 
wash buffer was able to remove the unrelated protein and 
scFv-Fc was successfully eluted under acidic condition. 
The purity of the purified scFv-Fc 183-H12-5C was 
more than 85%, and scFv-Fc was used for all subsequent 
immunoblot analysis. 
 
Binding of scFv 183-H12-5C and scFv-Fc 183-H12-5C 
against recombinant CA p24 and NL4-3 virus 
For binding analysis of scFv 183-H12-5C, the 
recombinant antibody format specifically captured 
recombinant p24 antigen evaluated by ELISA. 
Surprisingly, OD values were significantly lower than 
those obtain from wells coated with parental mAb-IgG 
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183-H12-5C. As expected, wells coated with BSA did 
not produce signals (Figure 6A). This result showed that 
scFv 183-H12-5C generated in reducing environment of 
mammalian cells specifically reacted with HIV-1-derived 
p24(gag) protein. 
For binding analysis of scFv-Fc 183-H12-5C, the format 
also specifically captured recombinant p24 antigen in 
ELISA setting. Interestingly, OD values were 
significantly no different between wells coated with 10 
or 1 μg of recombinant p24. As expected, wells coated 
with BSA did not produce signals. No signal provided 
when supernatant of HEK293T cells was used, 
confirmed the binding is specific by scFv-Fc 183-H12-
5C (Figure 6B). 
To further confirm the above results, Western blot 
analysis was performed. Recombinant p24, HIV-1 
(NL4.3) whole virus, and Nef (negative control) were 
electrophoresis resolved in 12% SDS-PAGE. The 
transferred proteins were washed and blocked before 
probed with purified scFv-Fc 183-H12-5C and parental 
antibody mAb-IgG 183-H12-5C. Detection of scFv-Fc 
183-H12-5C and mAb-IgG 183-H12-5C was done using 
HRP-conjugated anti-human and HRP-conjugated anti-
mouse. As expected, scFv-Fc 183-H12-5C specifically 
bind recombinant p24 and viral p24(gag). Interestingly, 
binding of scFv-Fc 183-H12-5C was stronger than 
binding of mAb-IgG 31-90-25 that routinely used for 
immunoblotting analysis (Figure 6C). Together both 
results of ELISA and Western blot showed that scFv 
183-H12-5C and scFv-Fc 183-H12-5C specifically 
reacted with recombinant p24 and HIV-1-derived 
p24(gag) protein. 
 
 
Figure 6. Binding analyses of scFv 183-H12-5C and scFv-Fc 183-H12-5C. Wells of ELISA plate were coated with various dilutions of 
scFv 183-H12-5C or their parental mAbs. 1 µg/mL of recombinant P24 was captured on immobilized scFv or parental mAbs and detected 
using HRP-conjugated secondary anti-P24 mAbs (31-90-25). Error bars show standard deviations calculated from at least two 
independent experiments each done in duplicate (A). Wells of ELISA plate were coated with either 1 µg/mL or 10 µg/mL of recombinant 
P24. 100 µL of 1ug/mL of scFv-Fc 183-H12-5C was added to capture immobilized recombinant p24 and detected using HRP-conjugated 
secondary anti-Human. Error bars show standard deviations calculated from at least two independent experiments each done in 
duplicate (B). Recombinant p24 and proteins extracted from HIV-1 virus were electrophoresed and transferred to nitrocellulose 
membranes. Immunoblotting with mAb-IgG 31-90-25 or scFv-Fc 183-H12-5C antibodies was carried out as described in materials and 
methods (C). 
 
scFv 183-H12-5C inhibits the replication-competent 
NL4-3 viral infectivity in Jurkat CD4+ T cell line. 
To determine the effect of the recombinant antibody on 
HIV-1 viral replication in CD4
+
 T cell, multi-round 
infectivity assay was performed. T-cell adapted 
laboratory strain virus such NL4-3 can be propagated in 
CD4
+
 T cell such Jurkat. The introduction of scFv 183-
H12-5C in this cell line by electroporation was 
hypothesized might affect the HIV viral replication.  
Jurkat T cells were transiently transfected with a plasmid 
expressing scFv 183-H12-5C by the electroporation 
method. Transfected cells then were infected with 
molecular clone of NL4-3 and the virus infectivity was 
monitored by MAGI infectivity assay. At MOI 0.1 with 
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mimicking natural infection process, virus infectivity of 
Jurkat expressing scFv were reduced by more than 60% 
from day one until day 4 (Figure 7A and 7B). Together 
this preliminary data showed that the scFv acted 
efficiently in inhibition of virus infectivity producing 
from CD4
+
 T cells.  
 
 
Figure 7. Kinetic analysis of HIV-1 infectivity on Jurkat T cell-scFv 183-H12- 5C infected with HIV-1 NL4-3 virus. To express 
intracellularly, pCDNA3.3-scFv 183-H12-5C plasmid vector was electroporated into Jurkat T and expressed constitutively under CMV 
promoter. Transiently expressing scFv 183-H12-5C-6His Jurkat T cells were infected with HIV-1 (NL4.3) at MOI 0.1 and culture 
supernatants were collected every 24 h and used in MAGI infectivity assay (A). Percentage of HIV-1 inhibition in Jurkat T cell transiently 
expressing scFv 183-H12-5C (B). The results are representative of three independent experiments each done in duplicate. 
 
Discussion 
Many studies highlighting the use of antibody from 
commercial hybridoma cell (clone 183-H12-5C) in 
detecting the HIV-1 capsid protein p24,
32,33
 however 
until now it has yet to be used for therapeutic purpose of 
HIV-1/AIDS. With the fact that monoclonal antibodies 
(mAbs) are highly specific and stable, it becomes an 
attractive candidate for in vivo treatment. Since 1992 
once FDA approved the first therapeutic mAb 
muromonab-CD3, 61 therapeutic mAbs approved by 
FDA until mid-2016.
34
 Although the number of approved 
mAbs is encouraging, most of them are limited to target 
surface antigens that make an intracellular protein such 
HIV-1 p24 is challenging. The initial part of developing 
antibody-based biotherapeutic is to test the antigenicity 
of anti-p24 mAb inside the target cells. However, 
antibodies do not readily permeate cell membranes, and 
thus the use of smaller fragment like scFv which easily 
expressing in the cytoplasm of mammalian is an option. 
Previously, the monovalent scFv antibody fragment 
against HIV-1 CA p24 had successfully isolated by 
phage display technology (data not shown). Expression 
of the scFv fusion in bacterial cells had shown high 
potential for production of functional scFv which then 
being used as detection reagent (data not shown). 
Although there was one recombinant antibody scFv 
against HIV-1 CA p24 produced using bacterial-based 
system had been reported recently, however no antiviral 
assays were performed using the format in order to 
validate its function in HIV replication and infectivity.
35
 
Here the expression of scFv in the human mammalian-
based system was reported and discussed for 
establishment of antibody-based biotherapeutic against 
HIV-1. 
Recombinant antibodies against HIV-1 p24 were 
recovered under two different forms: (i) as secreted 
soluble scFv molecules from the supernatant of 
pCDNA3.1-mIgG kappa-scFv 183-H12-5C-transfected 
HEK293T, and (ii) as scFv-Fc in the culture medium of 
pCMX2.5-hIgG1-scFv 183-H12-5C-Fc-transfected 
HEK293T. Both forms could be used as biological tools 
for different purposes such as soluble scFv potentially 
can be used as an intracellular antibody (intrabody) and 
scFv-Fc as a detection reagent. Here the study showed 
that the format expressed in mammalian reducing 
environment cytoplasm of HEK293T was able to react 
with recombinant p24 and HIV-1 derived p24 (gag). 
These findings suggest that the transient expression of 
scFv 183-H12-5C in HEK293T cells is not toxic to the 
cells and functionally active. In the case of soluble scFv-
Fc 183-H12-5C, the format could serve in conventional 
diagnostic assays for HIV-1 Gag detection, through 
specific recognition of the conserved CA p24 epitope. 
The format can replace the used of full-length IgG clone 
183-H12-5C produced from hybridoma system that 
expensive and time consuming. Indeed, it has been 
reported that hybridoma cells tend to lose their mAb 
productivity during long-term cultivation.
36,37
 
Furthermore, the constant region (Fc) plays a crucial role 
in the structural stability of the binding site and antibody 
conformation. Usually, the human IgG1 hinge region 
comprises of CH2 and CH3 was molecularly conjugated 
to the C-terminus of the scFv to generate the bivalent 
recombinant antibody. The presence of conserved 
cysteine amino acids in the constant part leads to the 
formation of disulfide bond which eventually associates 
the Fc region into dimers. The resulting bivalent 
recombinant antibody is known as scFv-Fv closely be 
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similar to the structure of intact IgG.
8
 The modifications 
aimed to increase the affinity of the monovalent scFv- Fc 
183-H12-5C against HIV-1 CA p24. The current results 
are consistent with the result obtained by Ray and group 
that showed a fusion of Fc region can enhance the 
activity of anti-GPRV scFv.
38
 
Moreover, a fusion of mouse origin scFv with human 
constant domains (CH2 and CH3) has proven to be 
beneficial in the clinical setting. Eliminating of the 
human anti-mouse antibody (HAMA) response can be 
simply achieved by generating the chimeric antibodies, 
humanized, and fully human antibodies.
39
 The anti- CEA 
scFv-Fc (H310A) chimeric antibody exhibited a low 
incidence of the HAMA response.
40
 These indicated that 
chimeric antibody is suitable for the assessment in the 
human clinical stage. Although the present study 
successfully obtained scFv-Fc 183-H12-5C, the reagent 
was used only for the detection analysis and not for 
biology assessment. The used of chimeric scFv-Fc 183-
H12-5C in HIV-1 replication inhibition will provide a 
benefit to the research community. For a reason, the role 
of scFv-Fc against HIV-1 replication is under 
investigation. 
To act as an intrabody, the scFv must be expressed in the 
mammalian target cells. The plasmid pCDNA3.3-scFv 
183-H12-5C-6His construct was transiently expressed in 
T cell line and the infectivity of HIV-1 was monitored. 
The finding revealed that intracellular expression of anti-
p24 scFv resulted in the production of functionally active 
intracellular antibodies (intrabodies) that interacted with 
incoming HIV capsid and prevented cells from 
producing the infectious viruses. No genomic integration 
of the gene of scFv when this type of expression was 
applied. Since the scFv was expressed episomally, over 
time the expression of the scFv is lost. Increasing of the 
infectious virus after day 4 of propagation may reflect 
from the phenomenon. Despite that, the transient 
expression is very useful in this study since it directly 
proved that scFv construct could be expressed well in 
Jurkat cell and at the same time can react with NL4-3 
virus which led to a decrease of infectious virus. The 
model system used was correlated with the report of 
effectiveness intrabodies against HIV-1 replication and 
infectivity.
14,19,20
 
Since the transient expression of scFv 183-H12-5C in 
Jurkat cell showed the potential clinical efficiency, stable 
expression was preferred for expressing the scFv. The 
correct integration that allows for scFv expression are 
small, and for that reason, several rounds of selective 
pressure in the form antibiotic supplementation needed to 
be applied for several weeks. However, stable production 
of scFv 183-H12-5C in Jurkat cells system under 
controlled of CMV promoter did not work. No 
expression of the recombinant antibody in developed cell 
line after selection process although the gene was still 
presented in the genome of the cells (data not shown). 
Integration of plasmid into chromosomes from cells 
grown under selective pressure analyzed by fluorescence 
in situ hybridization analysis (FISH) demonstrated that 
the integration constantly happened at a single site 
irrespective of the transfection method.
41
 This finding 
suggests that electroporation method was not the cause 
of the failure in the establishment of stable expressing 
scFv anti-p24 Jurkat cell line. Currently, to overcome the 
limitation, engineering the plasmid having another 
promoter and reporter gene for stably expressing of scFv 
and transfection efficiency determination in Jurkat cells 
respectively is undergoing.  
 
Conclusion 
In this work, the mammalian plasmid vectors expressing 
anti-p24 scFv were successfully engineered. ScFv and 
scFv-Fc were specifically expressed in a human 
mammalian-based expression system. The purified scFv 
and scFv-Fc showed good binding activity and 
specificity towards recombinant p24 and HIV-1 derived 
p24 (gag). Intracellular expression in relevant cells also 
demonstrated the effectiveness of inhibiting HIV-1 
replication and infectivity. The antibody could be used as 
candidates for the development of antibody-based 
biotherapeutics against HIV-1/AIDS. 
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